Pharmacyclics — Technical Presentation (December 2012)
21 slides from Pharmacyclics's technical presentation, Dec 10, 2012
Slide 1: Ibrutinib in combination with rituximab in high-risk CLL
The Btk inhibitor ibrutinib in combination with rituximab (iR) is well tolerated and displays profound activity in high-risk Chronic Lymphocytic Leukemia (CLL) patients. Jan A. Burger’, Michael J. Keating, William G. Wierda’, Julia Hoellenriegel', Alessandra Ferrajoli', Stefan Faderl', Susan Lernert
Slide 2: Targeting of BCR signaling with ibrutinib
TARGETING OF BCR SIGNALING WITH IBRUTINIB ° BTK (Bruton’s tyrosine kinase) inhibitors: ibrutinib (PCI-32765) Forms covalent bond with cysteine-481 in BTK ion, IC, = 0.5 nM ble with daily From: Nat Rev knmunol 2948 oS on ibrutinib
Slide 3: High-risk CLL
HIGH-RISK CLL ¢ Definition: ¢ del17p/TP53 mutation, or e del11q deletion, or e <3 years remission after first- line chemo-immunotherapy ¢ High-risk CLL patients have inferior responses to standard chemo- immunotherapy and shorter PFS and OS than low-risk patients ¢ There is no “standard” treatment f
Slide 4: Ibrutinib single agent (PCYC-1102-CA) in relapsed CLL: PFS
IBRUTINIB SINGLE AGENT (PCYC-1102- CA) IN RELAPSED CLL: PFS (O’Brien et al., EHA 2012, abstract #0542) 10 + Censored 09 08 —— 420 mg/day (N=27) —— 840 mg/day (N=34) PFS Probability a a T T T T T ™—T 0 2 4 6 8 10 12 14 #16 18 20 Months on Study
Slide 5: Ibrutinib single agent patient subgroup response
All Patients 41/61 270 years age 13/19 Bulky disease 2 5 cm 24/33 Bulky disease > 10 cm 7/10 70 | Hgb < 11 g/dL or PLT < 100K/uL at screening 22/36 61 igVHunmutated 31/42 4 B2 Microglobulin > 3mg/L 19/29 66 Purine Analog Refractory 17/28 61 {< 12 mos from any purine analog to next therapy)
Slide 6: Objectives
OBJECTIVES * Hypothesis: addition of rituximab to ibrutinib accelerates responses and increases ORR in high-risk CLL # Assess activity of ibrutinib and rituximab combination therapy (iR) in high-risk CLL/SLL (del17p/TP53 mutation or del11q deletion or < 3 years remission after first- line chemo-immu
Slide 7: Ibrutinib and rituximab (iR) in high-risk CLL
IBRUTINIB AND RITUXIMAB (IR) IN HIGH-RISK CLL ice dirle} Month 1 (375 mg/m2) TI] oY eae Cycle Ibrutinib 420 mg/d PO once daily Patients with benefit after 12 cycles will be allowed to continue on single-agent ibrutinib
Slide 8: Eligibility
ELIGIBILITY * Previously treated high-risk CLL (del17p, del11q, short remission after CIT) #* Patients with 17p deletion or TP53 mutation are not required to have received prior therapy * Treatment indication by 2008 IWCLL Criteria * Adequate renal and hepatic function
Slide 9: Patient characteristics (I)
PATIENT CHARACTERISTICS (I) Median Range Age (years) 65 (35-82) 62M (mg/L) 4.15 (2.2-12) WBC (x102/uL) 22.35 (2.2-298) ALC (x102/yL) 19,924 (377-276,954) # prior treatments 2.5 (0 - 8)
Slide 10: Patient characteristics (II)
PATIENT CHARACTERISTICS (Il) N % Rai stage 714 18 / 10% MW 6 15% IV 58% FISH 17p 50% cytogenetics 11q EK 13q 13% Neg 5% IGHV mutational Mutated 3% status Unmutated 80% Not Done 18%
Slide 11: Median lymphocyte counts chart
70000 Median (0125%-75% 60000 Non-Outlier Range 50000 40000 30000 20000 10000 t) Suto 1 2 3 4 8 12 16 20 2% 2
Slide 12: ‘Bvedan
‘Bvedan 25%-75% Non-Outlier Range
Slide 13: Del17p on iR
Del17p on iR Historic control (CIT salvage in del17p)* Fis. Failed Rx ‘40-2 Tortinib + Rtuximab (all pts) i 7 = 20 2 _Ibrutinib + Rituximab (17p- only) Median TTF: Si ocr (7p-Salvage pts)* 4.8 months *122 pt. from MDACC database
Slide 14: Weeks months iR before ibrutinib+R
2 weeks 3 months iR iR Before ibrutinib+R (iR)
Slide 15: Lymph node sites (31 evaluable patients)
Lymph node sites (31 evaluable patients) ° » a ~ a = a z a £ ° & 50: fa 5 Fy a ° oO i $ < orange = del17p, yellow = others
Slide 16: Spleen (31 evaluable patients)
Spleen (31 evaluable patients) = & an a : 2 H an £ : 2 a 2 s 3 a 4 A fi $ << orange = del17p, yellow = others
Slide 17: Before iR During iR
Before iR During iR
Slide 18: Response assessment at 6 months (N=40)
RESPONSE ASSESSMENT AT 3 —6 MONTHS (N=40) CR PR ORR PRw lymphocytosis Stable disease Too Early
Slide 19: iR: Toxicities (%)
IR: TOXICITIES (%) Anemia Mucositis Febrile Neutropenia Pneumonia Bruising Hot flashes Upper respiratory symptoms. Fatigue Bone pain, myalgias Diarrhea 2 patients off study: 1 aspergillosis, 1 oral ulcers
Slide 20: Biomarkers on iR therapy
BIOMARKERS ON IR THERAPY ccLs ccLs i 8 § £ = PRE 8 2 DAY7 a ‘ 5 DAY 14 = 8 DAY 28 PRE DAY7 DAY14 DAY28 PRE DAY7 DAY14 DAY28 Ibrutinib Irutinib ~(P=0.049), = 10 =£ > & 6 & 4 SBAFF assay by: Hermann Zz > Elbel, Centre of Chronic a Immunodeficiency Freiburg, 0. Germany & Matthias. Kreuzaler, Antonius R
Slide 21: Summary
SUMMARY IT’S TIME TO SAY * The combination of ibrutinib and m1 rituximab has profound activity in Sn ea high-risk CLL d 4 * High ORR (>80%), favorable toxicity profile, no hematotoxicity « Addition of rituximab may accelerate response compared to hy single agent ibrutinib ) # Open questions: remissi
Pharmacyclics — Technical Presentation (December 2012) on 6ix